for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NicOx SA

NCOX.PA

Latest Trade

3.33EUR

Change

0.05(+1.37%)

Volume

40,541

Today's Range

3.28

 - 

3.38

52 Week Range

2.53

 - 

5.23

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
3.28
Open
3.28
Volume
40,541
3M AVG Volume
0.90
Today's High
3.38
Today's Low
3.28
52 Week High
5.23
52 Week Low
2.53
Shares Out (MIL)
33.49
Market Cap (MIL)
117.22
Forward P/E
--
Dividend (Yield %)
--

Next Event

Nicox SA Annual Shareholders Meeting

Latest Developments

More

Nicox Selects New Drug Candidate For In-House Development Program

Nicox Q3 Net Revenue At EUR 0.8 Million

Nicox: Mississippi Phase 2 Trial For NCX 4251 To Start In Dec 2020

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About NicOx SA

Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The Company has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). It has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.

Industry

Biotechnology & Drugs

Contact Info

Drakkar 2 - Batiment D

2405 route des Dolines

CS 10313 Sophia Antipolis

06560

France

+33.4.97245300

http://www.nicox.com

Executive Leadership

Michele Garufi

Chairman of the Board and Chief Executive Officer, Member of the Management Committee

Sandrine Gestin

Finance Director, Member of the Management Committee

Michael Bergamini

Executive Vice President, Chief Scientific Officer, Member of the Management Committee

Gavin Spencer

Executive Vice President & Chief Business Officer, Member of the Management Committee

Emmanuelle Pierry

Senior Director of Legal Affairs, Member of the Management Committee

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (EUR)

2017

-0.310

2018

-0.630

2019

-0.620

2020(E)

-0.855
Price To Earnings (TTM)
--
Price To Sales (TTM)
32.16
Price To Book (MRQ)
1.23
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
19.95
LT Debt To Equity (MRQ)
15.37
Return on Investment (TTM)
-24.55
Return on Equity (TTM)
-22.59

Latest News

Latest News

BRIEF-Nicox Partner Ocumension Completes Successful Hong Kong IPO At About US$ 1.09 Bln Valuation

* REG-NICOX PARTNER OCUMENSION COMPLETES SUCCESSFUL HONG KONG IPO AT AN APPROXIMATELY US$ 1,090 MILLION VALUATION Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Nicox Sells Its Remaining Stake In VISUfarma For 5 Million Euros

* NICOX STRENGTHENS CASH POSITION WITH DIVESTMENT OF ITS VISUFARMA SHAREHOLDING

BRIEF-Sika Acquires Egyptian Market Leader In Roofing And Waterproofing Systems

* SIKA ACQUIRES MARKET LEADER IN ROOFING AND WATERPROOFING SYSTEMS IN EGYPT

BRIEF-Nicox Initiates First Phase 3 Trial Of NCX 470 In Glaucoma

* NCX 470 WILL COMPETE IN >$6 BILLION WORLDWIDE GLAUCOMA MARKET

BRIEF-Nicox Announces Q1 Net Revenue Of 1.7 Million Euros

* FIRST QUARTER 2020 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS

BRIEF-Nicox Outlines Plans To Progress NCX 4251 Into Phase 2b Trial

* OUTLINES PLANS TO PROGRESS NCX 4251 INTO PHASE 2B TRIAL FOLLOWING POSITIVE MEETING WITH FDA

BRIEF-Nicox: Partner Fera Pharmaceuticals Applies For Orphan Drug Designation For Naproxcinod

* REG-NICOX’S PARTNER FERA PHARMACEUTICALS FILES APPLICATION FOR ORPHAN DRUG DESIGNATION FOR NAPROXCINOD IN SICKLE-CELL DISEASE

BRIEF-Nicox Announces Zerviate Launch By Eyevance Pharmaceuticals In The U.S.

* ANNOUNCES ZERVIATE LAUNCH BY PARTNER EYEVANCE PHARMACEUTICALS IN THE UNITED STATES

BRIEF-Nicox Updates Agreement With Ocumension Therapeutics On ZERVIATE

* OCUMENSION'S ZERVIATE EXCLUSIVE RIGHTS EXPANDED TO INCLUDE SOUTH EASTERN ASIAN COUNTRIES

BRIEF-Nicox Says Ocumension Will Pay Nicox EUR 15 Million Under Amended Agreement

* NICOX TO RECEIVE €15 MILLION AND HALF OF THE COST OF THE SECOND NCX 470 PHASE 3 CLINICAL TRIAL FROM OCUMENSION THERAPEUTICS UNDER AMENDED AGREEMENT

BRIEF-Nicox Announces Additional Approval For Vyzulta In Taiwan

* NICOX SA TODAY ANNOUNCES THAT ITS PARTNER, BAUSCH + LOMB, HAS RECEIVED APPROVAL FOR VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024% IN TAIWAN. Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Nicox FY Net Revenue Up At 6.9 Million Euros

* NET LOSS OF NICOX GROUP FOR FULL YEAR 2019 WAS EUR 18.9 MILLION AGAINST EUR 18.4 MILLION IN FULL YEAR 2018

BRIEF-Nicox Completes End-of-Phase 2 Meeting With the U.S. FDA

* NICOX’S POSITIVE END-OF-PHASE 2 MEETING WITH THE U.S. FDA SETS STAGE FOR NCX 470 PHASE 3 PROGRAM IN GLAUCOMA

Nicox teams up with Chinese firm to develop and sell glaucoma drug

French ophthalmology company Nicox and Chinese firm Ocumension Therapeutics said on Monday they had signed an exclusive license agreement to develop and sell a yet-to-be approved Nicox drug to treat glaucoma in China.

Healthcare group Nicox postpones NASDAQ listing due to market volatility

French healthcare and ophthalmology company Nicox said it had decided to postpone plans to list shares on the U.S. NASDAQ stock market, in the latest example of a company dropping stock market flotation plans due to market volatility.

BRIEF-Nicox Q1 Net Revenue At 0.075 Million Euros

* AS OF MARCH 31, 2018, THE GROUP HAD CASH AND CASH EQUIVALENTS OF €36.3 MILLION AS COMPARED WITH €41.4 MILLION AT DECEMBER 31, 2017

BRIEF-Nicox Opening Of U.S. Development Office In Research Triangle Park, North Carolina

* REG-NICOX: OPENING OF U.S. DEVELOPMENT OFFICE IN RESEARCH TRIANGLE PARK, NORTH CAROLINA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Nicox Announces Increase In Royalties From Bausch + Lomb For Vyzulta

* REG-NICOX ANNOUNCES IMPROVED FINANCIAL TERMS FROM BAUSCH + LOMB FOR VYZULTA

BRIEF-Nicox Provides 2018 Outlook And 2017 Estimated Financial Results

* ZERVIATETM (CETIRIZINE OPHTHALMIC SOLUTION), 0.24%, U.S. LAUNCH PLANNED BY PARTNER EYEVANCE PHARMACEUTICALS FOR THE 2018 FALL ALLERGY SEASON

BRIEF-Nicox Updates on Drug Development And Outlines 2018 Activities

* RESOURCES IN 2018 WILL BE FOCUSED ON ADVANCING NICOX'S PIPELINE CANDIDATES NCX 470 AND NCX 4251 TOWARDS MID-STAGE CLINICAL DEVELOPMENT

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up